Armed with the first phase 3 data for their TROP2-targeting antibody-drug conjugate (ADC) datopotamab deruxtecan as a second-line treatment for breast cancer, AstraZeneca
AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a
A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d
AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just
Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a